The Hottest in Medical Cannabis Research: Fall 2018

The third quarter of the year was full large headlines for the cannabis industry. Epidiolex became the first cannabis-based medicine to acquire FDA-approval in america, Coca-Cola and Budweiser are planning to jump in the cannabis market, and cannabis companies are causing waves in the stock exchange. All of this excitement is enhanced from the groundbreaking research studies which deepen our understanding of cannabis ’ vast potential to improve wellness and our health. Listed below are five of the most exciting studies from this quarter.

Studies at a Glance:

The effect of cannabinoids is a young but growing field of scientific investigation. Various studies have demonstrated some terpenes, independently and the effects of cannabinoids. But it’s unknown if these anti-tumor effects could be enhanced through the “entourage effect” of multiple cannabinoids and terpenes working together to improve the treatment’s effectiveness.

The preparation that is whole-plant had more powerful anti-tumor effects than THC as predicted.

In  a recent research by scientists at Madrid, the entourage effect was put to the test on breast cancer tumors in female mice. Scientists compared the effect of THC against a whole-plant cannabis preparation from the ability to restrict tumor growth and kill its own cells. The preparation that is whole-plant had more powerful anti-tumor effects than THC as predicted. Interestingly, a combination therapy of just the five most abundant terpenes from the preparation had no effect on tumor development, either on its own or in combination with THC, suggesting that the anti-tumor properties of the whole-plant preparation resulted from a combination of the many cannabinoids.

These results provide critical support for the entourage effect, which remains mostly hypothetical for problems. However, these studies of whole-plant extracts provide insight that will cause the generation of medicines. It’s important to note, that cancer treatment is not a one-size-fits-all model, and every cancer has to be studied.

Traditionally, scientists’ understanding of nausea has been less complete than our understanding of the processes vomiting. A recent report by Canadian scientists provided important insight into brain mechanisms underlying nausea, and in doing this, identified CBD as an anti-nausea agent with potential to aid in the anti-nausea effects of THC and minimize its negative effects.

A recent report identified CBD as an agent with potential to aid in the anti-nausea effects of THC and minimize its negative effects.

The scientists reported that getting nauseas is related to an increase in the brain chemical in the brain&rsquo. Serotonin activation of the specific serotonin receptor type, 5-HT3, causes nausea. One of the chief methods that THC reduces nausea is by reducing serotonin in this brain area, and for that reason, reduces regeneration of the 5-HT3 receptor.

This study also demonstrated the CBD can reduce nausea by activating another serotonin receptor, called 5-HT1A. From the insula, by activating these receptors, serotonin levels can be reduced by blocking their release from cells.

Although untested in this study, the combination of CBD and THC may have profound effects that are anti-nausea through two mechanisms:

Together, this may reduce serotonin levels and the activation of the nausea-inducing 5-HT3 receptor. Since CBD can block some of THC’s effects through activities elsewhere in the brain, the approach may be the best and strategy for a lot of people. However, this hypothesis warrants further investigation.

The prevailing belief has been that cannabis increases risk for schizophrenia.

Rather than cannabis use risk for schizophrenia, this study suggests that schizophrenia increases cannabis use as a tool.

Scientists can get insight the role of influencers by comparing an individual’s DNA with their behaviour and personality traits. Predictive relationships may emerge as more subjects are included in the evaluation. In this instance , scientists identified a gene that has been associated with cannabis dependence and schizophrenia. They then used statistical methods to reveal that schizophrenia patients were more likely to use cannabis.

This study reverses our traditional understanding of the relationship between cannabis and schizophrenia. Rather than cannabis use risk for schizophrenia, this study suggests that schizophrenia increases cannabis use as a tool.

How may cannabis function as a tool that is self-medicating? According to 2 brain imaging studies, CBD can normalize brain activity. Disorganized thinking and cognitive impairments which result from brain activity characterizes schizophrenia. In one research , scientists discovered that CBD increased the potency of their communication patterns between the striatum and the prefrontal cortex, two brain areas involved in cognitive processing.

In another research , scientists discovered that CBD improved brain function during a learning task in those with a high risk for schizophrenia when compared with placebo. Together, both of these studies support the use of CBD as an anti-psychotic treatment in schizophrenia and purpose to why the many people who turn to cannabis for self-medication ought to be directed towards products with higher levels of CBD.

Clinical Trial Finds Benefits of CBD in Autism

There has been an accumulation of anecdotal reports of cannabis’ therapeutic success in autism spectrum disorder, but it remains one notable area where the studies have lagged. That appears to be changing.

The study was promising: 61 percent of parents believed that their kids ’s autism symptoms.

In an early-stage clinical trial of 60 Israeli children with autism spectrum disorder, scientists measured the effect of cannabis at a 20:1 CBD:THC ratio on a host of symptoms associated with the condition. The study was promising: 61 percent of parents believed that their kids ’s symptoms were improved by cannabis. Cannabis reduced anxiety in 39 percent and communication. Further, these subjects had levels of perceived stress and behaviors.

These exciting results have led scientists to launch a larger double-blinded placebo controlled research . Placebo-controlled studies are essential to eliminate outcomes which are inherent in studies that rely on reporting. Regardless of the limitation of bias, this study represents the first evaluation of cannabis in the treatment of autism spectrum disorder and its consequences are consistent with many of the anecdotal reports which have been shared through the years.

CBD has over 65 known targets in body and the brain which contribute to its wide spectrum of benefits. Since the CBD dose increases, so does the number of goals it affects. The effect CBD has at lower doses may be overridden by this and eliminate its therapeutic effectiveness. Identifying brain goals that low doses are affected at by CBD enhance compliance will make dosing easier, and reduce any negative effects that may occur due the interactions which high doses of CBD may have with the metabolism of other medications.

Identifying brain goals that CBD affects at doses will make dosing easier, improve patient compliance, and reduce.

Scientists working in Spain have recently revealed another CBD goal that is affected at low doses. They demonstrate that CBD blocks the action of sigma 1 receptors, which regulates some of the role of the brain’s NMDA receptors. Similar blockers of NMDA receptors are associated with improving outcomes after stroke and dampening pain.

Scientists measured its impact on the extent of brain damage following a stroke and pain responses and infused concentrations of CBD directly. From the pain tests, CBD improved the pain-relieving effects of morphine, enabling for longer, the mice to withstand pain. After stroke, mice that had been infused with CBD had less brain damage than those from the control group. In both cases, CBD was unsuccessful at reducing pain and improving stroke outcomes if rsquo; s DNA & the mice was altered such that there were not able to generate the sigma 1 receptor.

Beyond the importance of the sigma 1 receptor to rsquo & CBD;s benefits, these studies provide additional support to the concept that CBD may protect against brain damage due to trauma or stroke. There’s a growing number of studies which have found that having CBD from the body prior into a stroke restricts its damage. This is an area of future study.

Published at Wed, 24 Oct 2018 16:27:53 +0000

Posted in: Investing

Comments are closed.